Valuein

Overview

HCA Healthcare, Inc.

HCANYSEHealth CareServices-General Medical & Surgical Hospitals, NECCIK 0000860730Large-cap benchmark

Latest 10-K: FY2025, filed Feb 10, 2026 · Open the 10-K (Inline XBRL) ↗

Revenue
$75.60B
7.1%YoYup from FY2024
TotalRevenue
Gross profit
Not reported
Net income
$6.78B
17.8%YoYup from FY2024
NetIncome
Diluted EPS
$28.33
28.8%YoYup from FY2024
EPSDiluted
Diluted shares
239.5M
8.5%YoYdown from FY2024
WeightedAvgSharesDiluted

At a glance

Growth

  • HCA Healthcare, Inc. reported revenue of $75.60B for fiscal 2025, up 7.1% from fiscal 2024.
  • Revenue grew faster than the median S&P 500 member in 4 of the last 5 fiscal years.

Profitability

  • Net margin was 9.0%, against a median of 12.8% across S&P 500 members for the same fiscal year.

Per share

  • Diluted EPS was $28.33, up 28.8% from the prior year.
Loading insider and institutional summary

Written from the filed figures on this page by fixed rules — no AI.

Data as of Oct 31, 2026 · Sources: SEC EDGAR 10-K

Financial statements

Annual figures from the 10-K, most recent fiscal year first.

Income Statement

5 annual periods

Chip: YoY change.

Income Statement, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: large-cap benchmark median change. Line under a label: how many large-cap benchmark companies its median rests on.
Line itemFY2025FY2024FY2023FY2022FY20214Y CAGR
Revenue
$75.60B7.1%up
Benchmark median 6.4%
$70.60B8.7%up
Benchmark median 4.5%
$64.97B7.9%up
Benchmark median 4.8%
$60.23B2.5%up
Benchmark median 10.3%
$58.75B14.0%up
Benchmark median 13.8%
6.5%
Benchmark median 6.6%
Gross Profit
Median of 315 / 498
—
—
—
—
—
—
Benchmark median 6.2%
Operating Income
Median of 373 / 498
—
—
—
—
—
—
Benchmark median 7.2%
Net Income
$6.78B17.8%up
Benchmark median 4.8%
$5.76B9.9%up
Benchmark median 5.7%
$5.24B7.1%down
Benchmark median 1.9%
$5.64B18.9%down
Benchmark median 1.3%
$6.96B85.3%up
Benchmark median 33.9%
-0.6%
Benchmark median 4.1%
EPS (Diluted)
$28.3328.8%up
Benchmark median 6.2%
$22.0016.0%up
Benchmark median 7.9%
$18.970.9%down
Benchmark median 1.9%
$19.159.5%down
Benchmark median 1.5%
$21.1693.6%up
Benchmark median 34.8%
7.6%
Benchmark median 5.6%

Balance Sheet

5 annual periods

Chip: YoY change.

Balance Sheet, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: large-cap benchmark median change. Line under a label: how many large-cap benchmark companies its median rests on.
Line itemFY2025FY2024FY2023FY2022FY20214Y CAGR
Total Assets
$60.72B2.0%up
Benchmark median 5.6%
$59.51B5.9%up
Benchmark median 3.4%
$56.21B7.2%up
Benchmark median 4.1%
$52.44B3.3%up
Benchmark median 2.2%
$50.74B6.8%up
Benchmark median 6.7%
4.6%
Benchmark median 4.7%
Total Liabilities
Median of 357 / 498
—
—
—
—
—
—
Benchmark median 4.4%
Stockholders' Equity
negative: -$2.77B599.3%down
Benchmark median 6.8%
$0.56B47.6%down
Benchmark median 5.4%
$1.06Bn/m
Benchmark median 7.3%
negative: -$0.07B104.9%down
Benchmark median 2.5%
$1.49B48.5%down
Benchmark median 9.0%
n/m
Benchmark median 6.1%
Cash & Equivalents
$1.04B46.2%down
Benchmark median 5.2%
$1.93B106.7%up
Benchmark median 1.9%
$0.94B3.0%up
Benchmark median 6.7%
$0.91B37.4%down
Benchmark median -8.6%
$1.45B19.1%down
Benchmark median -2.9%
-8.0%
Benchmark median 2.0%
Total Debt
$46.49B8.0%up
Benchmark median 2.1%
$43.03B8.7%up
Benchmark median 0.2%
$39.59B4.0%up
Benchmark median 0.3%
$38.08B3973.2%up
Benchmark median 0.1%
$0.94B21.9%up
Benchmark median -0.1%
165.5%
Benchmark median 4.3%

Cash Flow Statement

5 annual periods

Chip: YoY change.

Cash Flow Statement, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: large-cap benchmark median change. Line under a label: how many large-cap benchmark companies its median rests on.
Line itemFY2025FY2024FY2023FY2022FY20214Y CAGR
Operating Cash Flow
$12.64B20.2%up
Benchmark median 6.3%
$10.51B11.5%up
Benchmark median 4.8%
$9.43B10.7%up
Benchmark median 9.9%
$8.52B4.9%down
Benchmark median -0.7%
$8.96B3.0%down
Benchmark median 10.7%
9.0%
Benchmark median 7.0%
Capital Expenditures
$4.94B1.4%up
Benchmark median 5.4%
$4.88B2.8%up
Benchmark median 2.8%
$4.74B7.9%up
Benchmark median 11.3%
$4.39B22.9%up
Benchmark median 14.0%
$3.58B26.2%up
Benchmark median 8.1%
8.4%
Benchmark median 9.0%
Free Cash Flow
Median of 378 / 498
$7.69B36.4%up
Benchmark median 7.3%
$5.64B20.3%up
Benchmark median 6.1%
$4.69B13.6%up
Benchmark median 8.8%
$4.13B23.3%down
Benchmark median -11.3%
$5.38B15.9%down
Benchmark median 10.2%
9.3%
Benchmark median 4.9%

n/m: not meaningful — the base (the prior year, or the first year for the CAGR) was zero or negative, or a per-share figure’s share basis changed (stock split). “—” means the figure is not available.

Benchmark median = median of the companies in the benchmark universe on Dec 31 of each fiscal year, from their own 10-K filings; a change counts only companies whose prior year was positive. Each median uses every member that reports the line item; where fewer than 80% do (banks and insurers file no gross profit), the row names how many. Published where at least 250 companies report it. Updated 2026-10-27. This compares reported figures, not share-price returns. Methodology

Ratios & valuation

FY2025

Every ratio read two ways: Wall Street’s popular formula and the value investor’s stricter one. Same question, same unit. Pick a ratio.

Valuation · Earnings yield

What a dollar of market value earned

6.1%

Wall Street

on net earnings

FY2024 7.3%

6.9%

Value investor

on free cash flow

FY2024 7.2%

Gap +0.8 pts: Value-investor figure 0.8 points higher

How it’s calculated

Wall Street · on net earnings

Diluted EPS ÷ fiscal-year-end share price (1 ÷ P/E)

pe_ratio (ratio table)

P/E 16.5×

Value investor · on free cash flow

(Operating cash flow − capital expenditures) ÷ market capitalisation (fiscal-year-end close × weighted-average diluted shares)

free cash flow ÷ market cap

Each ratio measures one thing two ways, in the same unit: the popular formula, then a stricter one, so a lower figure is the stricter reading. Gap = value-investor figure minus Wall Street figure, from the figures shown.

Price-based ratios use the fiscal-year-end closing price. Free cash flow = operating cash flow − capital expenditures (we compute it; filings rarely report it). n/m = not meaningful (denominator ≤ 0); “—” = not reported. Each ratio’s formulas are under “How it’s calculated”.

Loading capital allocation

Smart money

Loading insider and institutional activity

Showing the most recent 5 annual periods. Get longer history on the Pro plan, or the full history (1993–present) plus the smart-money dataset and webhooks on Institutional.

Peers, filings & research

Loading sector peers
Loading recent filings

Research Reports

No published research on HCA yet.

Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on HCA and publish the result to your public profile.

Loading the data behind this page

Cite this page

Data as of Oct 31, 2026. Canonical address: https://valuein.biz/data/HCA

APA-style text
Valuein. (2026, October 31). HCA Healthcare, Inc. (HCA) financial statements, earnings power and smart-money summary [Data set]. Source: SEC EDGAR filings. https://valuein.biz/data/HCA
BibTeX
@misc{valuein_hca_2026,
  author = {{Valuein}},
  title = {HCA Healthcare, Inc. (HCA) financial statements, earnings power and smart-money summary},
  year = {2026},
  howpublished = {\url{https://valuein.biz/data/HCA}},
  note = {Data as of 2026-10-31; source: SEC EDGAR filings}
}
Open 10-K in SEC Inline XBRL viewer

10-K filed Feb 10, 2026 · accession 0001193125-26-044769

Agents: every figure Valuein's tools return carries a fact_id that traces to its SEC filing.

point-in-time · survivorship-free · every number traceable to its SEC filing

Index names are trademarks of their owners; Valuein is not affiliated with or endorsed by any index provider.